Xerostomia (Dry Mouth Disease) Therapeutics Market Size and Outlook 2031

Report Description

Key Insights	Details
Forecast Period	2026 - 2031
Market Size (2025)	USD 1.84 Billion
CAGR (2026-2031)	4.0%
Fastest Growing Segment	Electro-stimulation devices
Largest Market	North America
Market Size (2031)	USD 2.33 Billion

Market Overview

The Global Xerostomia (Dry Mouth Disease) Therapeutics Market is expected to grow from USD 1.84 Billion in 2025 to USD 2.33 Billion by 2031 at a 4.0% CAGR. Xerostomia therapeutics address the subjective sensation of dry mouth, often caused by reduced salivary flow, encompassing a range of solutions including saliva substitutes, stimulants, and various over-the-counter and prescription medications. The market's expansion is primarily driven by the increasing global geriatric population, a rising incidence of chronic diseases such as Sjögren's syndrome and head and neck cancers, and the widespread use of medications known to induce dry mouth. According to the American Dental Association, in July 2026, more than 42% of medications have dry mouth as a side effect, significantly contributing to patient need. Additionally, growing awareness regarding the oral health complications associated with untreated xerostomia fuels demand for effective therapeutic interventions.

A significant challenge impeding market growth is the limited efficacy and often short duration of action characteristic of many currently available symptomatic treatments. Furthermore, certain prescription sialogogues possess undesirable side effects, which can restrict their clinical utility and impact patient adherence. The persistent issue of underdiagnosis and under-recognition of xerostomia also delays timely intervention, thus hindering broader market expansion.

Key Market Drivers

Rising Prevalence of Xerostomia-Inducing Conditions
The increasing prevalence of xerostomia-inducing conditions significantly propels the global xerostomia therapeutics market. This includes chronic autoimmune disorders such as Sjögren's syndrome, which directly impairs salivary gland function, and the widespread use of various medications known to cause dry mouth as a side effect. For instance, according to a systematic review and meta-analysis published in ResearchGate in September 2026, the overall prevalence of Sjogren's syndrome in the world was estimated at 13%. Such a substantial affected population underscores a persistent and growing demand for effective symptomatic relief and therapeutic interventions to manage this debilitating condition across diverse patient groups.

Aging Population and Polypharmacy as Market Drivers
The growing geriatric population and associated polypharmacy also represent a primary driver for market expansion. Older adults frequently suffer from multiple chronic conditions, leading to the concurrent use of several medications, a phenomenon known as polypharmacy. Many of these medications are known to induce xerostomia, exacerbating the problem within this demographic. According to Fangyuan Tian et al., in a study published in the J Gerontol A Biol Sci Med Sci in July 2026, the pooled global prevalence of polypharmacy in older adults was 50.4%. This high prevalence, combined with an aging global populace, ensures a sustained and expanding patient pool requiring xerostomia therapeutics. Furthermore, the global incidence of head and neck cancer, a significant cause of radiation-induced xerostomia, reached approximately 931,000 new cases in 2026, according to the World Cancer Research Fund, further contributing to the overall market need for effective dry mouth treatments.

Download Free Sample Report

Key Market Challenges

Underdiagnosis and Under-Recognition Impede Market Growth
The persistent issue of underdiagnosis and under-recognition of xerostomia significantly impedes the expansion of the global xerostomia therapeutics market. When individuals experiencing symptoms of dry mouth are not accurately diagnosed, they remain unaware of their condition and the available treatment options. This directly translates to a substantial portion of the affected population not seeking therapeutic interventions, thereby restricting the overall patient pool and limiting market demand for specialized solutions.

Underdiagnosis Limits Treatment Uptake and Market Growth
Further compounding this challenge, According to the International Association for Dental, Oral, and Craniofacial Research (IADR), in March 2026, xerostomia affects one out of five people globally, yet it is frequently an underdiagnosed and overlooked medical condition. This means a considerable number of individuals who could benefit from saliva substitutes, stimulants, or prescription medications are not entering the treatment pathway. The delay in timely identification and intervention results in symptoms progressing without management, which diminishes the potential for early and sustained adoption of therapeutics, directly hindering market growth.

Key Market Trends

Regenerative and gene therapies targeting salivary gland dysfunction.
Advancements in regenerative and gene therapies are fundamentally reshaping xerostomia treatment by moving beyond symptomatic relief to addressing underlying salivary gland dysfunction. This trend involves developing solutions that restore damaged salivary gland function through cellular repair or genetic modification, offering potential for long-term, curative outcomes. These innovative approaches aim to overcome the temporary effects and undesirable side effects of current palliative treatments. For instance, according to the National Institute of Dental and Craniofacial Research, in March 2026, a $440,275 grant was awarded to University at Buffalo researchers for salivary gland repair and regeneration. This emphasizes a growing focus on durable therapeutic interventions.

AI-driven personalization for individualized xerostomia care.
The emergence of AI-driven treatment personalization is significantly enhancing xerostomia management by tailoring interventions to individual patient needs. AI platforms analyze extensive patient data, including medical histories and genetic profiles, to identify optimal therapeutic strategies and predict efficacy. This personalization enables more targeted drug selection, optimized dosages, and proactive side effect management, improving patient outcomes and adherence. Supporting this, according to the National Institute of Dental and Craniofacial Research, in September 2026, a $3.1 million grant was awarded to researchers at the Eastman Institute for Oral Health to develop an AI platform for predicting, diagnosing, and treating oral diseases. This illustrates growing integration of sophisticated analytical tools for individualized patient care.

Segmental Insights

Rapid growth of electro-stimulation devices in xerostomia therapeutics
The electro-stimulation devices segment is experiencing rapid growth within the Global Xerostomia (Dry Mouth Disease) Therapeutics Market due to its distinct advantages over traditional treatments. These devices offer a non-pharmacological, drug-free approach, directly stimulating the body’s natural salivary production without the systemic side effects associated with conventional medications. This minimally invasive method significantly improves patient comfort and compliance, leading to sustained relief and enhanced oral health-related quality of life. As patients increasingly seek effective alternatives free from adverse drug reactions, the adoption of electro-stimulation devices continues to accelerate globally.

Regional Insights

North America-s Market Leadership Fueled by Prevalence, Infrastructure, and Proactive Initiatives
North America holds a leading position in the global xerostomia therapeutics market due to the significant prevalence of dry mouth conditions, frequently associated with an aging population, polypharmacy, and extensive cancer therapies. The region benefits from a robust healthcare infrastructure, high patient awareness of dry mouth symptoms, and proactive treatment-seeking behavior. Strong adoption of both over-the-counter and prescription therapies is evident across the region. Additionally, initiatives from organizations like the American Dental Association and the Sjögren's Foundation contribute to increased diagnosis and comprehensive management, further solidifying North America's market leadership.

Recent Developments

In October 2025, Hydronovo, a company co-founded by researchers from the University of California, San Francisco (UCSF), received accelerated funding from the federal Small Business Innovation Research (SBIR) program. This funding was directed towards advancing Ceviginate, their pioneering regenerative treatment for severe dry mouth caused by salivary gland dysfunction, particularly following radiation therapy for head and neck cancers. Ceviginate works by restoring the native biology disrupted by radiation, using an injectable hydrogel solution to promote stem cell proliferation and ultimately restore gland function. This significant investment is preparing the company for large-scale manufacturing and safety studies, impacting the future of regenerative therapies in the global xerostomia therapeutics market.
In August 2025, Novartis announced that two Phase III clinical trials for ianalumab, NEPTUNUS-1 and NEPTUNUS-2, met their primary endpoint in patients with Sjögren's disease. This systemic autoimmune condition frequently results in severe dry eyes and dry mouth for over 90% of affected individuals. The trials demonstrated a statistically significant reduction in disease activity and showed improvements in patient burden. Novartis's ianalumab, a fully human monoclonal antibody, has the potential to become the first targeted treatment for Sjögren's disease, offering a new therapeutic option for the dry mouth component within the global xerostomia therapeutics market.
In July 2025, Forward Science, an innovator in oral health solutions, officially launched SalivaGUM™. This new product was introduced as a convenient, on-the-go solution specifically designed to help alleviate dry mouth symptoms. SalivaGUM™ complements the company's existing SalivaMAX® product line by offering a daily-use option for individuals seeking moisture and comfort throughout the day. Sweetened with xylitol and infused with calcium, the gum supports oral wellness and provides fast-acting relief, indicating an expansion in the range of consumer-accessible products within the global xerostomia therapeutics market.
In May 2025, the U.S. Food and Drug Administration granted Fast Track designation to a novel cell therapy developed by the Program for Advanced Cell Therapy, a collaboration between UW Health and the UW School of Medicine and Public Health. This designation was for a treatment aimed at xerostomia, or dry mouth, specifically that caused by radiation therapy. The therapy, which was in a Phase 1 clinical trial at the UW Health | Carbone Cancer Center, offered a regenerative medicine approach utilizing mesenchymal stromal cells to restore salivary gland function. This regulatory milestone was anticipated to expedite the development and review process for this promising therapeutic in the global xerostomia therapeutics market, addressing a significant unmet medical need for patients with chronic dry mouth.

Key Market Players

3M
ADVANZ PHARMA Corp.
Church & Dwight Co., Inc.
Colgate-Palmolive Company
Fresenius Kabi
GlaxoSmithKline plc
Lupin Limited
OraCoat (OraHealth)
Parnell Pharmaceuticals Inc.
Perrigo Company plc

By Therapeutic Modality	By Product Form	By Distribution Channel	By Region
Artificial Saliva / Saliva Substitutes Salivary Stimulants Electro-stimulation Devices Other Therapeutic Modalities	Sprays Gels Lozenges / Pastilles Mouthwashes / Rinses Other Product Forms	Retail Pharmacies Hospital Pharmacies Online Pharmacies	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Xerostomia (Dry Mouth Disease) Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Xerostomia (Dry Mouth Disease) Therapeutics Market, By Therapeutic Modality:

Artificial Saliva / Saliva Substitutes
Salivary Stimulants
Electro-stimulation Devices
Other Therapeutic Modalities

Xerostomia (Dry Mouth Disease) Therapeutics Market, By Product Form:

Sprays
Gels
Lozenges / Pastilles
Mouthwashes / Rinses
Other Product Forms

Xerostomia (Dry Mouth Disease) Therapeutics Market, By Distribution Channel:

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

Xerostomia (Dry Mouth Disease) Therapeutics Market, By Region:

North America

United States
Canada
Mexico

Europe

France
United Kingdom
Italy
Germany
Spain

Asia Pacific

China
India
Japan
Australia
South Korea

South America

Brazil
Argentina
Colombia

Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Xerostomia (Dry Mouth Disease) Therapeutics Market.

Available Customizations:

Global Xerostomia (Dry Mouth Disease) Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Xerostomia (Dry Mouth Disease) Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Therapeutic Modality (Artificial Saliva / Saliva Substitutes, Salivary Stimulants, Electro-stimulation Devices, Other Therapeutic Modalities)

5.2.2. By Product Form (Sprays, Gels, Lozenges / Pastilles, Mouthwashes / Rinses, Other Product Forms)

5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

5.2.4. By Region

5.2.5. By Company (2025)

5.3. Market Map

6. North America Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Therapeutic Modality

6.2.2. By Product Form

6.2.3. By Distribution Channel

6.2.4. By Country

6.3. North America: Country Analysis

6.3.1. United States Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Therapeutic Modality

6.3.1.2.2. By Product Form

6.3.1.2.3. By Distribution Channel

6.3.2. Canada Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Therapeutic Modality

6.3.2.2.2. By Product Form

6.3.2.2.3. By Distribution Channel

6.3.3. Mexico Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Therapeutic Modality

6.3.3.2.2. By Product Form

6.3.3.2.3. By Distribution Channel

7. Europe Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Therapeutic Modality

7.2.2. By Product Form

7.2.3. By Distribution Channel

7.2.4. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Therapeutic Modality

7.3.1.2.2. By Product Form

7.3.1.2.3. By Distribution Channel

7.3.2. France Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Therapeutic Modality

7.3.2.2.2. By Product Form

7.3.2.2.3. By Distribution Channel

7.3.3. United Kingdom Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Therapeutic Modality

7.3.3.2.2. By Product Form

7.3.3.2.3. By Distribution Channel

7.3.4. Italy Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Therapeutic Modality

7.3.4.2.2. By Product Form

7.3.4.2.3. By Distribution Channel

7.3.5. Spain Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Therapeutic Modality

7.3.5.2.2. By Product Form

7.3.5.2.3. By Distribution Channel

8. Asia Pacific Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Therapeutic Modality

8.2.2. By Product Form

8.2.3. By Distribution Channel

8.2.4. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Therapeutic Modality

8.3.1.2.2. By Product Form

8.3.1.2.3. By Distribution Channel

8.3.2. India Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Therapeutic Modality

8.3.2.2.2. By Product Form

8.3.2.2.3. By Distribution Channel

8.3.3. Japan Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Therapeutic Modality

8.3.3.2.2. By Product Form

8.3.3.2.3. By Distribution Channel

8.3.4. South Korea Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Therapeutic Modality

8.3.4.2.2. By Product Form

8.3.4.2.3. By Distribution Channel

8.3.5. Australia Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Therapeutic Modality

8.3.5.2.2. By Product Form

8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Therapeutic Modality

9.2.2. By Product Form

9.2.3. By Distribution Channel

9.2.4. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Therapeutic Modality

9.3.1.2.2. By Product Form

9.3.1.2.3. By Distribution Channel

9.3.2. UAE Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Therapeutic Modality

9.3.2.2.2. By Product Form

9.3.2.2.3. By Distribution Channel

9.3.3. South Africa Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Therapeutic Modality

9.3.3.2.2. By Product Form

9.3.3.2.3. By Distribution Channel

10. South America Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Therapeutic Modality

10.2.2. By Product Form

10.2.3. By Distribution Channel

10.2.4. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Therapeutic Modality

10.3.1.2.2. By Product Form

10.3.1.2.3. By Distribution Channel

10.3.2. Colombia Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Therapeutic Modality

10.3.2.2.2. By Product Form

10.3.2.2.3. By Distribution Channel

10.3.3. Argentina Xerostomia (Dry Mouth Disease) Therapeutics Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Therapeutic Modality

10.3.3.2.2. By Product Form

10.3.3.2.3. By Distribution Channel

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Xerostomia (Dry Mouth Disease) Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. 3M

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. ADVANZ PHARMA Corp.

15.3. Church & Dwight Co., Inc.

15.4. Colgate-Palmolive Company

15.5. Fresenius Kabi

15.6. GlaxoSmithKline plc

15.7. Lupin Limited

15.8. OraCoat (OraHealth)

15.9. Parnell Pharmaceuticals Inc.

15.10. Perrigo Company plc

16. Strategic Recommendations

17. About Us & Disclaimer

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Xerostomia (Dry Mouth Disease) Therapeutics Market in 2025?

Which is the dominating region in the Global Xerostomia (Dry Mouth Disease) Therapeutics Market?

Which is the fastest growing segment in the Global Xerostomia (Dry Mouth Disease) Therapeutics Market?

What is the expected growth rate of the Global Xerostomia (Dry Mouth Disease) Therapeutics Market?